论文部分内容阅读
目的观察孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘的疗效。方法选择医院2015年6月-2016年12月收治的咳嗽变异性哮喘患儿80例作为研究对象,随机分为治疗组和对照组,每组40例。对照组给予布地奈德吸入治疗,治疗组在此基础上给予孟鲁司特钠咀嚼片口服治疗,比较2组患儿的治疗效果。结果治疗组总有效率为95.0%明显高于对照组的72.5%,差异有统计学意义(P<0.05);治疗组咳嗽症状缓解时间、咳嗽消失时间均短于对照组,差异均有统计学意义(P<0.05);治疗前2组肿瘤坏死因子α(TNF-α)、白细胞介素8(IL-8)和免疫球蛋白E(Ig E)无统计学意义(P>0.05),治疗后2组TNF-α、IL-8、Ig E均有降低,且治疗组明显低于对照组,差异均有统计学意义(P<0.05)。结论孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘具有良好的临床效果,是临床治疗中可以采取的有效手段。
Objective To observe the curative effect of combination of montelukast and budesonide on cough variant asthma in children. Methods Eighty children with cough variant asthma admitted from June 2015 to December 2016 in our hospital were randomly divided into treatment group and control group, 40 cases in each group. The control group was given budesonide inhalation therapy, the treatment group was given montelukast sodium chewable tablets oral treatment on this basis, the treatment effect of two groups were compared. Results The total effective rate was 95.0% in the treatment group was significantly higher than 72.5% in the control group, the difference was statistically significant (P <0.05); the treatment group cough relief time, disappearance of cough were shorter than the control group, the difference was statistically significant (P <0.05). The levels of tumor necrosis factor alpha (TNF-α), interleukin 8 (IL-8) and IgE in the two groups before treatment were not significantly different (P> 0.05) The levels of TNF-α, IL-8 and IgE in the latter two groups were lower than those in the control group, and the differences were statistically significant (P <0.05). Conclusion Montelukast combined with budesonide in children with cough variant asthma has a good clinical effect, is an effective clinical treatment can be taken.